Heart Failure Management with Sacubitril/Valsartan
Patient Selection and Indications
- The American College of Cardiology recommends Entresto (sacubitril/valsartan) for patients with heart failure with reduced ejection fraction (HFrEF) with EF ≤40%, NYHA class II-IV symptoms, and currently on ACE inhibitor or ARB therapy 1
- Patients with HFrEF, persistent NYHA class II symptoms despite current therapy, and currently on an ACE inhibitor are eligible for sacubitril/valsartan therapy 1
Clinical Outcomes and Benefits
- The PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced the risk of cardiovascular death or heart failure hospitalization by 20% compared to enalapril in patients with HFrEF, with a number needed to treat of 21 over 27 months 1
- Sacubitril/valsartan improves left ventricular ejection fraction, decreases left ventricular end-diastolic and end-systolic volumes, and improves diastolic function parameters 1
Treatment Initiation and Monitoring
- A 36-hour washout period is required when switching from an ACE inhibitor to sacubitril/valsartan to avoid angioedema, and the lowest dose (24/26 mg twice daily) should be started for patients previously on low-dose ACE inhibitors 1
- Entresto should be titrated up every 2-4 weeks as tolerated toward a target dose of 97/103 mg twice daily, and blood pressure, renal function, and potassium levels should be monitored within 1-2 weeks after initiation 1
Concomitant Therapy and Contraindications
- The American College of Cardiology recommends continuing beta-blocker and statin therapy, and considering adding a mineralocorticoid receptor antagonist (MRA) if not already prescribed, as triple therapy with ARNI, beta-blocker, and MRA provides optimal outcomes 2
- Contraindications to Entresto include history of angioedema related to previous ACE inhibitor or ARB therapy, concomitant use with ACE inhibitors, severe hepatic impairment, and pregnancy 1